Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications
S Banerjee, MRA Pillai, FF Knapp - Chemical reviews, 2015 - ACS Publications
Interest in the use of radionuclides for treatment of various diseases has a long history and
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
parallels the isolation of radium by Marie and Pierre Curie in the early part of the 20th …
[HTML][HTML] Lutetium-labelled peptides for therapy of neuroendocrine tumours
BLR Kam, JJM Teunissen, EP Krenning… - European journal of …, 2012 - Springer
Abstract Treatment with radiolabelled somatostatin analogues is a promising new tool in the
management of patients with inoperable or metastasized neuroendocrine tumours …
management of patients with inoperable or metastasized neuroendocrine tumours …
Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer
M Benešová, M Schäfer, U Bauder-Wüst… - Journal of Nuclear …, 2015 - Soc Nuclear Med
Despite many advances in the past years, the treatment of metastatic prostate cancer still
remains challenging. In recent years, prostate-specific membrane antigen (PSMA) inhibitors …
remains challenging. In recent years, prostate-specific membrane antigen (PSMA) inhibitors …
ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms: peptide receptor radionuclide therapy with radiolabelled somatostatin …
The purpose of these guidelines is to assist physicians caring for patients with
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide …
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG
I Kayani, JB Bomanji, A Groves… - … Journal of the …, 2008 - Wiley Online Library
BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer
68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission …
68Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission …
First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu-and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra …
K Herrmann, M Schottelius, C Lapa, T Osl… - Journal of nuclear …, 2016 - Soc Nuclear Med
Chemokine receptor 4 (CXCR4) is a key factor for tumor growth and metastasis in several
types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand …
types of human cancer. Based on promising experiences with a radiolabeled CXCR4 ligand …
[HTML][HTML] Radiolabeled peptides: valuable tools for the detection and treatment of cancer
M Fani, HR Maecke, SM Okarvi - Theranostics, 2012 - ncbi.nlm.nih.gov
Human cancer cells overexpress many peptide receptors as molecular targets.
Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor …
Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor …
Targeting prostate cancer: prostate‐specific membrane antigen based diagnosis and therapy
T Wüstemann, U Haberkorn, J Babich… - Medicinal research …, 2019 - Wiley Online Library
The high incidence rates of prostate cancer (PCa) raise demand for improved therapeutic
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …
strategies. Prostate tumors specifically express the prostate‐specific membrane antigen …
[HTML][HTML] Overview of radiolabeled somatostatin analogs for cancer imaging and therapy
R Eychenne, C Bouvry, M Bourgeois, P Loyer… - Molecules, 2020 - mdpi.com
Identified in 1973, somatostatin (SST) is a cyclic hormone peptide with a short biological half-
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
life. Somatostatin receptors (SSTRs) are widely expressed in the whole body, with five …
[HTML][HTML] Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER …
Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP)
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …
elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In …